Brief: Olezarsen SNDA Accepted By The FDA For Priority Review
26/02/2026 12:21
Feb 26 (Reuters) - Ionis Pharmaceuticals Inc IONS.O: OLEZARSEN SNDA ACCEPTED BY THE FDA FOR PRIORITY REVIEW FOR THE TREATMENT OF SEVERE HYPERTRIGLYCERIDEMIA (SHTG) IONIS PHARMACEUTICALS INC - FDA HAS SET A PRESCRIPTION DRUG USER FEE ACT (PDUFA) TARGET ACTION DATE OF JUNE 30, 2026 Source text: ID:nBw9CPpSPa Further company coverage: IONS.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Ionis Pharmaceuticals
See all newsUS FDA approves GSK's hepatitis B drug, offering patients chance to stop long-term treatment (updated)
US FDA approves GSK's hepatitis B drug, offering patients chance to stop long-term treatment
Focus: AI companies run virtual drug trials, aim to improve success of human studies
Brief: Ionis Pharmaceuticals Says Ulefnersen Demonstrates Favorable Safety And Tolerability Profile
Otsuka, Ionis' experimental ALS drug meets main goal in late-stage study